Skip to content

Study · Randomized controlled trial · n = 20 · 2020

5 results

Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers.

Winzeler B, da Conceição I, Refardt J, Sailer CO, Dutilh G, Christ-Crain M

Endocrine4 Jul 2020Cited by 28 (Europe PMC)

PMID32623637 (opens in a new tab)DOI10.1007/s12020-020-02394-2 (opens in a new tab)PepBankPUB-32623637
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, total fluid intake was numerically lower with dulaglutide than placebo, without statistical significance.

    In plain wordsIn healthy volunteers, fluid intake was lower with dulaglutide than placebo, but the difference was not statistically significant.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeTotal fluid intake
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Electrolyte balance · Kidney and urinary
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Measurements

    Median fluid intake
    1300 ml
    dulaglutide
    Median fluid intake
    1600 ml
    placebo
    Median fluid intake difference
    −100 ml
    dulaglutide versus placebo

    Source sentences

    Summary
    Median [IQR] total fluid intake was 1300 ml [888-1600] versus 1600 ml [1000-1720], on dulaglutide and placebo treatment, p = 0.06.
    3 context sentences
    Summary · context
    The median [IQR] difference of fluid intake on dulaglutide compared to placebo treatment was -100 ml [-400-0].
    Summary · context
    Double-blind, randomized, placebo-controlled, crossover study.
    Summary · context
    20 healthy volunteers received dulaglutide 1.5 mg and placebo (0,9% sodium chloride) subcutaneously once weekly for 3 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, food intake was identical during dulaglutide and placebo treatment.

    In plain wordsIn healthy volunteers, food intake was identical with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeFood intake
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    All but four participants drank less on dulaglutide versus placebo treatment despite identical food intake.
    2 context sentences
    Summary · context
    Double-blind, randomized, placebo-controlled, crossover study.
    Summary · context
    20 healthy volunteers received dulaglutide 1.5 mg and placebo (0,9% sodium chloride) subcutaneously once weekly for 3 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, urine output was lower with dulaglutide than placebo.

    In plain wordsIn healthy volunteers, urine output was lower with dulaglutide than placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseUrine output
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Electrolyte balance · Kidney and urinary
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Measurements

    Median 24-h urine output
    1250 ml
    dulaglutide
    Median 24-h urine output
    1680 ml
    placebo

    Source sentences

    Summary
    Median [IQR] 24-h urine output was reduced in dulaglutide versus placebo-treated participants: 1250 ml [975-2080] versus 1680 ml [1400-2040], p = 0.04.
    2 context sentences
    Summary · context
    Double-blind, randomized, placebo-controlled, crossover study.
    Summary · context
    20 healthy volunteers received dulaglutide 1.5 mg and placebo (0,9% sodium chloride) subcutaneously once weekly for 3 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, median serum sodium was equal with dulaglutide and placebo.

    In plain wordsIn healthy volunteers, median blood sodium was equal with dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeSerum sodium
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Electrolyte balance · Kidney and urinary
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Measurements

    Median sodium
    140 mmol/L
    both visits

    Source sentences

    Summary
    Median serum sodium levels were 140 mmol/L on both visits and no difference in thirst perception was noted.
    2 context sentences
    Summary · context
    Double-blind, randomized, placebo-controlled, crossover study.
    Summary · context
    20 healthy volunteers received dulaglutide 1.5 mg and placebo (0,9% sodium chloride) subcutaneously once weekly for 3 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, thirst perception did not differ between dulaglutide and placebo.

    In plain wordsIn healthy volunteers, thirst did not differ between dulaglutide and placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeThirst perception
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Electrolyte balance · Kidney and urinary
    Studied dose
    1.5 mg once weekly · subcutaneous · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Median serum sodium levels were 140 mmol/L on both visits and no difference in thirst perception was noted.
    2 context sentences
    Summary · context
    Double-blind, randomized, placebo-controlled, crossover study.
    Summary · context
    20 healthy volunteers received dulaglutide 1.5 mg and placebo (0,9% sodium chloride) subcutaneously once weekly for 3 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.